RCKT250117C7500
- 4.10
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Rocket Pharmaceuticals Initiated at Buy by Jefferies
Jefferies Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $29
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $40
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55
Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity
Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52
Cantor Fitzgerald Remains a Buy on Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Rocket Pharmaceuticals Analyst Ratings
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51
J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $49
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $29 to $52